We rank companies based on fund manager, research analyst and news sentiment
IBRX stock icon

ImmunityBio
IBRX

$5.27
7.74%
 

About: ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.

Employees: 628

0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

242% more capital invested

Capital invested by funds: $84M [Q3] → $287M (+$203M) [Q4]

96% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 28

87% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 15

10% more funds holding

Funds holding: 129 [Q3] → 142 (+13) [Q4]

1.12% more ownership

Funds ownership: 7.45% [Q3] → 8.57% (+1.12%) [Q4]

27% less call options, than puts

Call options by funds: $2.92M | Put options by funds: $3.99M

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$5
5%
downside
Avg. target
$5
5%
downside
High target
$5
5%
downside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Piper Sandler
Joseph Catanzaro
5%downside
$5
Neutral
Maintained
25 Mar 2024

Financial journalist opinion